April 6, 2023 7:21am

The market seems to be more hung-up with macro-economic data concern than with healthcare equities

Pre-open Indications: 3 Positive Indications <jump shots>

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

The 8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday …

 

Dow futures are UP +0.05% or (+13 points), S&P futures are UP +0.02% or (+1 point) and NASDAQ futures are DOWN -0.21% or (-28 points) early in the pre-open – so far

Stock futures were mixed and fluctuating on Thursday,

European markets mixed,

Asia-Pacific markets mostly fell.

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

The Nasdaq lost nearly 1.1%. The S&P 500 dipped about 0.3%, while the Dow bucked the trend, rising 0.2% in part because of outperformance from health-care stocks.

A good quote for the a.m. post, ““The market is now becoming more concerned about the ensuing data as opposed to the Fed and trying to pick where the Fed is going to hit peak interest rates. Plenty of the Street is thinking, ‘Recession, right?’ The market has to start to price for that, because that’s not where we’re priced, so bad news definitely has to be bad news.” <CNBC, Rob Haworth, senior vice president and senior investment strategist at U.S. Bank Wealth Management>

Economic Data Docket: jobless claims data for more insights into the strength of the labor market. St. Louis Fed President James Bullard is also slated to speak in the morning in Arkansas.

 

Wednesday’s (4/5) … RegMed Investors’ (RMi) closing bell: “the cell and gene therapy sector just can’t get a break. I am contemplating a share pricing ascension due to being grossly oversold as weakening economics reign.” …  https://www.regmedinvestors.com/articles/12904

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … “The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth” … https://www.regmedinvestors.com/articles/12843 --- 31 of 35 (my coverage group) added BLUE, BCLI, OTCQB: BSTG and ADVM

 

Ebb and flow:

Q2/23 – 3 negative closes

Q1/23 –

·         March – ended with 10 positive and 13 negative closes

·         February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

·         January – 2 holidays, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Not much to say, a holiday due – escapism reigns with decreased trading and volume

Positive indications:

Wednesday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed down -$1.88 with a positive +$1.20 or +0.60% aftermarket indication.

Beam Therapeutics (BEAM) closed down -$0.25 with a positive +$0.58 or +1.98% aftermarket indication.

Voyager Therapeutics (VYGR) closed down -$0.01 after Tuesday’s -$0.41 and Monday’s +$0.41 with a positive +$0.10 or +1.30% aftermarket indication

 

 

The BOTTOM LINE: I try to keep it simple and short!

Last session of the shortened week, I reiterate …” Recessionary scares have been depriving the cell and gene therapy sector of appreciation.”

Electronic trading and algorithms will be lusting for the oversold, maybe not immediately.

Reiterating, “A SUSTAINABLE uptrend is needed to get credibility BACK into the sector’s investment”

April showers did NOT quite bring... a strong sector first trading session advance as remnants of fear continue to inhabit markets; although, expectation is still up in the air hoping to appear within new sessions of April

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product.

And I can always be WRONG but, I am mostly EARLY!

Also, the rush of Q4 and FY22 earnings to release is slowing …

·         31 of my 35 covered have reported - 4 remaining

·         Waiting for remaining release announcements …

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.